alon
unlik
benefici
prophylaxi
treatment
sar
cov
infect
clinic
trial
ifna
might
justifi
determin
benefici
effect
outcom
sar
lish
antivir
treatment
patient
sar
sar
primarili
diagnos
process
clinicalepidemiolog
exclus
despit
improv
recent
past
laboratori
diagnosi
particularli
molecular
detect
viru
polymeras
chain
reaction
remain
unreli
especi
first
day
diseas
addit
test
yet
valid
serolog
analysi
thought
confirmatori
laboratori
test
patient
sar
develop
detect
igg
antibodi
level
week
onset
symptom
thu
differenti
diagnosi
remain
problem
clinician
time
initi
present
particularli
individu
without
known
exposur
patient
sar
histori
travel
region
sar
endem
casefat
rate
reflect
part
lack
effect
specif
treatment
viral
infect
broadspectrum
antibiot
treat
communityacquir
bacteri
pneumonia
glucocorticoid
ribavirin
administ
patient
sar
efficaci
unknown
recent
glycyrrhizin
demonstr
inhibit
sarsrel
cov
sar
cov
vitro
ribavirin
use
basi
abil
inhibit
cov
also
show
inhibitori
effect
sever
rna
virus
bunyavirus
arenavirus
support
search
effect
antivir
treatment
evalu
suscept
sar
cov
isol
detail
studi
perform
isol
toronto
canada
ribavirin
interferon
ifn
vitro
data
indic
ribavirin
inhibit
viru
concentr
attain
human
serum
may
use
deserv
evalu
therapeut
agent
materi
method
studi
perform
recent
sequenc
isol
obtain
toronto
patient
gener
find
confirm
use
addit
independ
obtain
isol
toronto
patient
isol
origin
nasopharyng
swab
vero
cell
atcc
use
suscept
studi
cell
maintain
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
gibco
brl
vero
cell
infect
moi
sar
cov
h
adsorpt
supernat
replac
dmem
contain
variou
amount
ribavirin
mgml
iuml
scheringplough
h
immunoblot
analysi
cell
lysat
analyz
sdspage
tri
gel
protein
electrotransf
polyvinyl
iden
difluorid
membran
immobilon
p
membran
millipor
viral
antigen
detect
use
enhanc
chemiluminesc
use
patient
serum
sampl
horseradish
peroxidaseconjug
antihuman
igg
plaqu
assay
confluent
vero
cell
infect
dilut
sar
cov
min
infect
inoculum
remov
cell
monolay
overlaid
lowmeltingpoint
agaros
dmem
without
titer
determin
h
infect
follow
crystal
violet
stain
microassay
vero
cell
infect
sar
cov
moi
min
incub
dmem
contain
variou
amount
iuml
h
infect
cell
formalin
fix
remov
biocontain
analyz
use
phasecontrast
microscopi
use
axiovert
microscop
zeiss
result
vitro
studi
conduct
vero
cell
one
limit
number
cell
line
suscept
sar
cov
vero
cell
monolay
treat
ribavirin
variou
concentr
mgml
h
treatment
initi
concurr
inocul
cell
cultur
viru
moi
inhibit
viral
cytopath
effect
cpe
use
determin
antivir
effect
drug
reduct
cpe
detect
day
compar
untreat
control
sampl
viral
titer
determin
tissu
cultur
supernat
ident
treat
untreat
cell
amount
pfuml
data
shown
ribavirin
test
concentr
time
greater
mgml
inhibit
replic
ribavirinsensit
virus
arenavirus
bunyavirus
evid
sar
cov
suscept
action
ribavirin
ifn
suscept
demonstr
sever
coronavirus
mous
hepat
viru
porcin
transmiss
gastroenter
viru
felin
infecti
periton
viru
human
coronaviru
inhibitori
concentr
rang
iuml
iuml
therefor
test
suscept
isol
scheringplough
brief
vero
cell
infect
moi
either
h
time
treatment
iuml
treatment
continu
h
cpe
use
demonstr
antivir
effect
indic
figur
cpe
day
infect
significantli
decreas
cultur
treat
iuml
treatment
group
compar
untreat
control
group
indic
pretreat
necessari
protect
effect
tissu
cultur
data
shown
almost
complet
protect
achiev
infect
vero
cell
treat
iuml
quantifi
effect
replic
sar
cov
vero
cell
infect
moi
incub
presenc
iuml
describ
h
cell
supernat
harvest
determin
protein
express
immunoblot
analysi
viru
yield
plaqu
titrat
vero
cell
indic
figur
concentr
iuml
substanti
reduc
viru
yield
log
decreas
viru
yield
achiev
dose
iuml
reduct
viru
yield
seem
relat
decreas
viru
growth
support
chang
plaqu
morpholog
figur
inhibit
viral
protein
express
investig
use
immunoblot
analysi
sdspage
cell
lysat
figur
serum
sampl
patient
sar
seroconvert
sar
cov
use
detect
viral
protein
earlier
studi
shown
serum
sampl
react
strongli
nucleocapsid
protein
sar
cov
viral
protein
express
reduc
concentr
iuml
abolish
concentr
iuml
confirm
effect
addit
independ
sar
cov
isol
obtain
canadian
patient
sar
determin
isol
show
pattern
inhibit
b
analysi
celltocel
spread
sar
cov
presenc
sd
absenc
vero
cell
monolay
infect
dilut
sar
cov
h
viru
adsorpt
inoculum
remov
cell
monolay
overlaid
lowmeltingpoint
agaros
dmem
dmem
contain
iuml
day
infect
cell
stain
crystal
violet
c
protein
analysi
cell
lysat
subject
sdspage
protein
electrotransf
polyvinyliden
difluorid
membran
immobilon
p
membran
millipor
viral
antigen
detect
use
patient
serum
sampl
horseradish
peroxidaseconjug
antihuman
igg
use
enhanc
chemiluminesc
np
nucleoprotein
comparison
effect
antivir
activ
differ
sar
cov
isol
vero
cell
infect
independ
isol
sar
cov
isol
analyz
sensit
describ
isol
figur
isol
ic
iuml
present
studi
demonstr
sar
cov
suscept
ribavirin
high
concentr
even
ad
time
infect
contrast
viru
inhibit
tissu
cultur
concentr
iuml
although
relationship
vitro
serum
ifn
concentr
biolog
effect
known
peak
serum
ifn
concentr
least
iuml
observ
intramuscular
im
inject
iuml
similar
ifn
serum
concentr
iuml
im
inject
report
studi
patient
hepat
c
viru
hcv
associ
system
vascul
dose
iuml
infus
intraven
might
achiev
serum
concentr
rang
observ
inhibit
sar
cov
present
data
serum
level
ifna
patient
sar
would
help
treatment
vitro
studi
thu
far
perform
vero
cell
signific
vero
cell
shown
ifn
gene
defici
thu
unabl
express
endogen
ifn
howev
ifndepend
pathway
function
activ
exogen
provid
ifn
test
limit
number
differ
cell
line
hela
crfk
suscept
sar
cov
thu
far
fail
identifi
anoth
line
support
viral
replic
data
shown
observ
vero
cell
clone
propag
viru
may
inde
relat
lack
function
ifn
system
thu
support
find
present
studi
despit
effort
group
other
grow
viru
differ
rodent
speci
small
anim
model
yet
establish
recent
cynomolgu
macaqu
macaca
fasciculari
infect
sar
cov
induc
similar
clinic
symptom
patholog
find
human
sar
limit
number
anim
use
present
studi
remain
determin
futur
whether
cynomolgu
macaqu
suitabl
model
sar
thu
antivir
vivo
studi
anim
model
definit
establish
might
justifi
consid
clinic
trial
ifn
alreadi
approv
human
use
determin
whether
ifn
benefici
effect
outcom
sar
cov
infect
combin
observ
lack
efficaci
ribavirin
patient
sar
vitro
data
support
conclus
ribavirin
least
alon
unlik
benefici
prophylaxi
treatment
sar
cov
infect
whether
combin
therapi
ribavirin
would
inhibit
replic
sar
cov
vitro
yet
evalu
combin
effect
either
agent
use
alon
treatment
hcv
infect
human
